Email not displaying correctly? View it in your browser
Forward to a colleague | Sign up to the BNF newsletter

Newsletter
January 2020

Welcome to the January BNF Newsletter.

• Three new drug monographs have been added to the BNF in the last month: gilteritinib, meropenem with vaborbactam, and neratinib.
• MHRA advice on ambrisentan (Volibris®), carfilzomib (Kyprolis®), and yellow fever vaccine, live.

Kind regards,
BNF Team

Other topics:

Significant changes   |   Drug Safety Update

Significant changes

BNF BNF only

New monograph: Nerlynx® [neratinib] for HER2-overexpressed/amplified breast cancer (specialist use only).

New monograph: Vaborem® [meropenem with vaborbactam] for complicated urinary-tract infection [including pyelonephritis], complicated intra-abdominal infection, hospital-acquired pneumonia, ventilator-associated pneumonia, bacteraemia [occurring in association with or suspected to be associated with the licensed indications], and aerobic Gram-negative infections [in patients with limited treatment options] (administered on expert advice).

New monograph: Xospata® [gilteritinib] for FLT3 mutation-positive acute myeloid leukaemia (specialist use only).

New preparations: Pepto-Bismol® [bismuth subsalicylate] for Helicobacter pylori eradication [in combination with other drugs (see Helicobacter pylori infection)].

New preparations: Softacort® [hydrocortisone eye drops] for local treatment of conjunctival inflammation (short-term).

Ambrisentan (Volibris®): patient alert card available [MHRA/CHM advice].

Carfilzomib (Kyprolis®): risk of reactivation of hepatitis B virus [MHRA/CHM advice].

Chronic obstructive pulmonary disease: updated guidance on management.

Dyspepsia, Gastro-oesophageal reflux disease, and Peptic ulcer disease: updated guidance and dosing regimens.

Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy [NICE guidance].

Helicobacter pylori infection: updated guidance and dosing regimens.

Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab [NICE guidance].

Pentosan polysulfate sodium for treating bladder pain syndrome [NICE guidance].

Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer [NICE guidance].

BNF BNF for Children Both BNF and BNF for Children

Asthma, acute: updated guidance on management.

Asthma, chronic: updated guidance on management.

Yellow fever vaccine, live: stronger precautions in people with weakened immunity and in those aged 60 years or older [MHRA/CHM advice].

BNF for Children BNF for Children Only

Gastro-oesophageal reflux disease: updated guidance.

 
Drug Safety Update
 

Drug Safety Update is a monthly newsletter from the MHRA and Commission on Human Medicine. Please follow this link to review the latest Drug Safety Update.

Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents.

 
 

News

Please donate old copies of the BNF
The PharmAid Scheme is an initiative of the Commonwealth Pharmacists Association where recent versions of medicines information resources including the BNF are redistributed to low and middle income countries. You can make a difference in another commonwealth country by simply donating your old BNF copies to them.

For more information on this scheme see commonwealthpharmacy.org/what-we-do/pharmaid/. If you would like to donate your copy email: admin@commonwealthpharmacy.org.

 
 

How to purchase BNF

 
Print

Print
online

Online
Subscription

Subscription
eBook

eBook
 
 
 

Newsletter Feedback
Please let us know if there are any issues that you'd like us to address in our newsletters. We welcome your feedback. If you have any comments or suggestions, please let us know at marketing@rpharms.com.

SIGN UP

Copyright © 2020 BMJ Publishing Group Ltd and the Royal Pharmaceutical Society of Great Britain. All rights reserved.

Terms of use

Copyright © 2020 BMJ Publishing Group Ltd, the Royal Pharmaceutical Society of Great Britain and RCPCH Publications. All rights reserved.

If you want to unsubscribe from emails from Pharmaceutical Press click here.

Pharmaceutical Press, 66-68 East Smithfield, London, E1W 1AW, United Kingdom.